MyFinsight
Home
Blog
About
Contact
Download
Download image
Net income (gain)
attributable to common...
-$3,289,639
Net income (gain)
-$3,287,051
Net loss (income) at
subsidiary attributable to...
$2,588
Income (loss) before
income taxes
-$3,137,100
Co-commercialization investment loss
-$146,080
Income tax expense
$3,871
Interest income
$78,031
Product Sancuso
$2,928,634
Product Vibativ
$2,118,295
Product Talicia
$1,916,481
Product Kristalose
$981,483
Product Caldolor
$965,564
Product Other
$168,850
Product Acetadote
$51,981
Revenues, including
adjustments-Product Omeclamox Pak
$517
Revenues, including
adjustments-Product Vaprisol
$1
Operating income (gain)
-$3,129,292
Interest expense
$85,839
Net revenues
$9,131,317
Revenues, including
adjustments-Product Redi Trex
-$489
Total costs and
expenses
$12,260,609
Selling and marketing
$5,064,875
General and
administrative
$2,554,475
Cost of products sold
$1,933,889
Research and development
$1,458,436
Amortization
$1,248,934
Back
Back
Income Statement
CUMBERLAND PHARMACEUTICALS INC (CPIX)
CUMBERLAND PHARMACEUTICALS INC (CPIX)
source: myfinsight.com